This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Value Biotech ETFs & Stocks to Buy Now
by Sanghamitra Saha
Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.
The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.
Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.
Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be reported quarter.
Bristol-Myers (BMY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Bristol-Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View
by Zacks Equity Research
Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
Glaxo (GSK) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Glaxo (GSK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Bayer's (BAYRY) earnings beat and revenues rise on the back of growth across all reported segments in the third quarter. The company updates guidance to include impact of discontinued operations.
Glaxo (GSK) Beats Earnings & Revenue Estimates in Q3
by Zacks Equity Research
Glaxo beats both earnings and sales estimates in the third quarter of 2019.
AMETEK (AME) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
AMETEK's (AME) third-quarter results are expected to reflect benefits of growth strategies and acquisitions, and solid momentum across segments.
Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View
by Zacks Equity Research
Pfizer (PFE) beats estimates for third-quarter earnings and sales and raises earnings guidance range for 2019 while tightening revenue outlook.
Factors Setting the Tone for Bristol-Myers (BMY) Q3 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.
Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sanofi's (SNY) Specialty Care and Vaccines units are likely to have driven third- quarter earnings.
Etsy (ETSY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Etsy's (ETSY) third-quarter results are likely to reflect strengthening product portfolio, mobile app and free shipping services.
Myriad Genetics Test to Identify Cancer Patients Gets FDA Nod
by Zacks Equity Research
Myriad Genetics (MYGN) moves a step toward advanced treatment by identifying women with ovarian cancer, who are currently receiving chemotherapy.
Lattice (LSCC) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Lattice Semiconductor's (LSCC) third-quarter results are likely to reflect solid momentum across communications and computing, and industrial and automotive markets.
Waters (WAT) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Waters' (WAT) third-quarter 2019 results are likely to have benefited from solid momentum across pharma market, U.S. and China.
Universal Display (OLED) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Universal Display (OLED) third-quarter results are expected to have benefited from growing proliferation of OLED panels in ADAS, wearables, drones and AR/VR devices.
Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat
by Zacks Equity Research
Gilead (GILD) falls short of earnings estimates but marginally beats on sales in the third quarter of 2019.
Pharma Stock Roundup: LLY, NVS, AZN's Q3 Earnings, Updates From FDA
by Kinjel Shah
Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) release Q3 results. FDA approves Glaxo's (GSK) Zejula and AstraZeneca's Farxiga for more patients. CHMP gives nod to several drugs
IPG Photonics (IPGP) to Report Q3 Earnings: What to Expect?
by Zacks Equity Research
Macroeconomic headwinds amid significant exposure to China are likely to have impacted IPG Photonics' (IPGP) third-quarter performance.
The Zacks Analyst Blog Highlights: Microsoft, Comcast, AT&T, Amgen and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Comcast, AT&T, Amgen and GlaxoSmithKline